{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:09:13Z","timestamp":1791727753993,"version":"4.3.4"},"reference-count":122,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The limited efficacy of traditional cancer treatments, including chemotherapy, radiotherapy, and surgery, emphasize the significance of employing innovative methods. CAR (Chimeric Antigen Receptor) T-cell therapy remains the most revolutionizing treatment of pediatric hematological malignancies and solid tumors. Patient\u2019s own lymphocytes are modified ex-vivo using gene transfer techniques and programmed to recognize and destroy specific tumor cells regardless of MHC receptor, which probably makes CAR-T the most personalized therapy for the patient. With continued refinement and optimization, CAR-T cell therapy has the potential to significantly improve outcomes and quality of life for children with limited treatment options. It has shown remarkable success in treating hematological malignancies, such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). However, its effectiveness in treating solid tumors is still being investigated and remains an area of active research. In this review we focus on solid tumors and explain the concept of CAR modified T cells, and discuss some novel CAR designs that are being considered to enhance the safety of CAR T-cell therapy in under-mentioned cancers. Furthermore, we summarize the most crucial recent reports concerning the solid tumors treatment in children. In the end we provide a short summary of many challenges that limit the therapeutic efficacy of CAR-T in solid tumors, such as antigen escape, immunosuppressive microenvironment, poor trafficking, and tumor infiltration, on-target off-tumor effects and general toxicity.<\/jats:p>","DOI":"10.3390\/jcm12062326","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T02:29:59Z","timestamp":1679020199000},"page":"2326","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["CAR T-Cell Therapy in Children with Solid Tumors"],"prefix":"10.3390","volume":"12","author":[{"given":"Marika","family":"Kulczycka","sequence":"first","affiliation":[{"name":"Student\u2019s Scientific Association, Department of Pediatric Hematology, Oncology and Transplantation, Medical University of Lublin, G\u0119bali 6, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Derlatka","sequence":"additional","affiliation":[{"name":"Student\u2019s Scientific Association, Department of Pediatric Hematology, Oncology and Transplantation, Medical University of Lublin, G\u0119bali 6, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Tasior","sequence":"additional","affiliation":[{"name":"Student\u2019s Scientific Association, Department of Pediatric Hematology, Oncology and Transplantation, Medical University of Lublin, G\u0119bali 6, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8760-0775","authenticated-orcid":false,"given":"Monika","family":"Lejman","sequence":"additional","affiliation":[{"name":"Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, G\u0119bali 6, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7207-156X","authenticated-orcid":false,"given":"Joanna","family":"Zawitkowska","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, G\u0119bali 6, 20-093 Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1542\/pir.2017-0057","article-title":"Pediatric Solid Tumors of Infancy: An Overview","volume":"39","author":"Whittle","year":"2018","journal-title":"Pediatr. Rev."},{"key":"ref_3","first-page":"3855","article-title":"Tumor microenvironment: Recent advances in various cancer treatments","volume":"12","author":"Wang","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","author":"Pan","year":"2017","journal-title":"Leukemia"},{"key":"ref_6","unstructured":"(2023, February 19). National Cancer Institute, Available online: https:\/\/nccrexplorer.ccdi.cancer.gov\/."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: Next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The Principles of Engineering Immune Cells to Treat Cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The urgent need to recover MHC class I in cancers for effective immunotherapy","volume":"39","author":"Garrido","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2114254","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_11","first-page":"373","article-title":"Pediatric brain tumors","volume":"21","author":"Wells","year":"2015","journal-title":"Continuum"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"867154","DOI":"10.3389\/fimmu.2022.867154","article-title":"CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies","volume":"13","author":"Antonucci","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/neuonc\/noaa278","article-title":"Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery","volume":"23","author":"Haydar","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41591-020-0827-2","article-title":"Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","volume":"26","author":"Donovan","year":"2020","journal-title":"J. Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1038\/s41467-021-23817-2","article-title":"P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas","volume":"12","author":"Mastandrea","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e004450","DOI":"10.1136\/jitc-2021-004450","article-title":"Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors","volume":"10","author":"Foster","year":"2022","journal-title":"J. Immunother. Cancer."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/neuonc\/noab300","article-title":"Dual IGF1R\/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant","volume":"24","author":"Pellegrino","year":"2022","journal-title":"Neuro-Oncology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/08830185.2022.2102619","article-title":"B7-H3-targeted CAR-T cell therapy for solid tumors","volume":"41","author":"Li","year":"2022","journal-title":"Int. Rev. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","article-title":"B7-H3: An Attractive Target for Antibody-based Immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","article-title":"Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors","volume":"26","author":"Theruvath","year":"2002","journal-title":"J. Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"616334","DOI":"10.3389\/fsurg.2021.616334","article-title":"Spinal Cord Diffuse Midline Glioma with Histone H3 K27M Mutation in a Pediatric Patient","volume":"8","author":"Cheng","year":"2021","journal-title":"Front. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","article-title":"Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas","volume":"24","author":"Mount","year":"2018","journal-title":"J. Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: An interim analysis","volume":"27","author":"Vitanza","year":"2021","journal-title":"J. Nat. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40425-018-0340-z","article-title":"Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells","volume":"6","author":"Nellan","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_28","unstructured":"(2023, February 19). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03638167."},{"key":"ref_29","unstructured":"(2023, February 19). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05298995."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.3389\/fimmu.2018.02380","article-title":"CAR T Cell Therapy for Neuroblastoma","volume":"9","author":"Richards","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ijc.1457","article-title":"Targeting of GD2-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes","volume":"94","author":"Rossig","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"J. Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"eabd6169","DOI":"10.1126\/scitranslmed.abd6169","article-title":"Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma","volume":"12","author":"Straathof","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1007\/s00432-021-03839-5","article-title":"GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and\/or recurrent neuroblastoma in pediatric patients","volume":"148","author":"Yu","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_37","unstructured":"(2023, February 19). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01460901."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13045-021-01193-0","article-title":"Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma","volume":"14","author":"Tumino","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/1078-0432.CCR-16-2138","article-title":"Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells","volume":"23","author":"Tanaka","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_40","unstructured":"(2023, February 19). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04539366."},{"key":"ref_41","unstructured":"(2023, February 19). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03721068."},{"key":"ref_42","unstructured":"(2023, February 19). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02107963."},{"key":"ref_43","unstructured":"(2023, February 19). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03635632."},{"key":"ref_44","unstructured":"(2023, February 19). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02919046."},{"key":"ref_45","unstructured":"(2023, February 19). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04637503."},{"key":"ref_46","unstructured":"(2023, February 19). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03294954."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.mt.6300104","article-title":"Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma","volume":"15","author":"Park","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_48","unstructured":"(2023, February 19). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02311621."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ijrobp.2018.01.110","article-title":"Timing of Radiation Therapy in Pediatric Wilms Tumor: A Report from the National Cancer Database","volume":"101","author":"Stokes","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Psys."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.1158\/0008-5472.CAN-04-4244","article-title":"Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling","volume":"65","author":"Capurro","year":"2005","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00043426-200111000-00006","article-title":"Glypican-3 expression in Wilms tumor and hepatoblastoma","volume":"23","author":"Toretsky","year":"2001","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/1097-0215(20000920)89:5<418::AID-IJC4>3.0.CO;2-I","article-title":"Expression of glypican 3 (GPC3) in embryonal tumors","volume":"89","author":"Saikali","year":"2000","journal-title":"Int. J. Cancer"},{"key":"ref_53","unstructured":"(2023, February 19). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04377932."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.18632\/oncotarget.27389","article-title":"EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma","volume":"10","author":"Ravanpay","year":"2019","journal-title":"Oncotarget"},{"key":"ref_55","unstructured":"(2023, February 19). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03618381."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.4049\/jimmunol.172.4.2352","article-title":"Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains","volume":"172","author":"Steinberger","year":"2004","journal-title":"J. Immunol."},{"key":"ref_57","unstructured":"(2023, February 19). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04483778."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13045-020-01012-y","article-title":"GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma","volume":"13","author":"Park","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1158\/0008-5472.CAN-11-2778","article-title":"Genetically modified T cells targeting interleukin-11 receptor \u03b1-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases","volume":"72","author":"Huang","year":"2012","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/jso.23368","article-title":"Overexpression of fibroblast activation protein and its clinical implications in patients with osteosarcoma","volume":"108","author":"Yuan","year":"2013","journal-title":"J. Surg. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41417-020-00221-4","article-title":"Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours","volume":"28","author":"Hsu","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.ejca.2005.03.015","article-title":"Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing\u2019s sarcoma","volume":"41","author":"Scotlandi","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/mt.2009.133","article-title":"Immunotherapy for osteosarcoma: Genetic modification of T cells overcomes low levels of tumor antigen expression","volume":"17","author":"Ahmed","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/cgt.2011.83","article-title":"Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma","volume":"19","author":"Rainusso","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cncr.28461","article-title":"Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma","volume":"120","author":"Roth","year":"2014","journal-title":"Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/2326-6066.CIR-15-0230","article-title":"Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas","volume":"4","author":"Long","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_69","first-page":"674","article-title":"GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas","volume":"10","author":"Chulanetra","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1158\/0008-5472.CAN-19-3579","article-title":"PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors","volume":"80","author":"Murty","year":"2020","journal-title":"Cancer Res."},{"key":"ref_71","unstructured":"(2023, February 19). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04897321."},{"key":"ref_72","unstructured":"(2023, February 19). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04864821."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Huang, X., Park, H., Greene, J., Pao, J., Mulvey, E., Zhou, S.X., Albert, C.M., Moy, F., Sachdev, D., and Yee, D. (2015). IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0133152"},{"key":"ref_74","unstructured":"(2023, February 19). Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05312411."},{"key":"ref_75","unstructured":"(2023, February 19). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04433221."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nrclinonc.2014.26","article-title":"Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies","volume":"11","author":"Linch","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s10637-016-0336-9","article-title":"Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors","volume":"34","author":"Shah","year":"2016","journal-title":"Investig. New Drugs"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.humpath.2011.03.010","article-title":"Ectomesenchymoma with t(1;12)(p32;p13) evolving from embryonal rhabdomyosarcoma shows no rearrangement of ETV6","volume":"43","author":"Howley","year":"2012","journal-title":"Hum. Pathol."},{"key":"ref_79","first-page":"1565","article-title":"Flow cytometric phenotype of rhabdomyosarcoma bone marrow metastatic cells and its implication in differential diagnosis with neuroblastoma","volume":"28","author":"Bozzi","year":"2008","journal-title":"Anticancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e17572","DOI":"10.1097\/MD.0000000000017572","article-title":"CD56-chimeric antigen receptor T-cell therapy for refractory\/recurrent rhabdomyosarcoma: A 3.5-year follow-up case report","volume":"98","author":"Jiang","year":"2019","journal-title":"Medicine"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1038\/s41467-020-17175-8","article-title":"Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma","volume":"11","author":"Hegde","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1542\/neo.22-7-e423","article-title":"Update on the Treatment of Retinoblastoma","volume":"22","author":"Manrique","year":"2021","journal-title":"NeoReviews"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Andersch, L., Radke, J., Klaus, A., Schwiebert, S., Winkler, A., Schumann, E., Grunewald, L., Zirngibl, F., Flemmig, C., and Jensen, M.C. (2019). CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6131-1"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s43018-020-00119-y","article-title":"GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision","volume":"1","author":"Wang","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"100971","DOI":"10.1016\/j.tranon.2020.100971","article-title":"GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma\u2014Assessing tumor and T cell interaction","volume":"14","author":"Sujjitjoon","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"707211","DOI":"10.3389\/fimmu.2021.707211","article-title":"A Novel Treatment for Ewing\u2019s Sarcoma: Chimeric Antigen Receptor-T Cell Therapy","volume":"12","author":"Lin","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nrc3627","article-title":"VEGF targets the tumour cell","volume":"13","author":"Goel","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1158\/1078-0432.CCR-07-0133","article-title":"Suppression of Ewing\u2019s sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy","volume":"13","author":"Zhou","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ejca.2006.01.063","article-title":"Clinical significance of Vascular Endothelial Growth Factor\u2014A expression in Ewing\u2019s sarcoma","volume":"42","author":"Kreuter","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e28313","DOI":"10.1002\/pbc.28313","article-title":"VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma","volume":"67","author":"Englisch","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_91","first-page":"17","article-title":"IGF1R immunohistochemistry in Ewing\u2019s sarcoma as predictor of response to targeted therapy","volume":"14","author":"Gonzalez","year":"2020","journal-title":"Int. J. Health Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"101240","DOI":"10.1016\/j.tranon.2021.101240","article-title":"Anti-GD2 CAR MSCs against metastatic Ewing\u2019s sarcoma","volume":"15","author":"Golinelli","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_93","unstructured":"(2023, February 19). Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03356782."},{"key":"ref_94","unstructured":"(2023, March 10). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04099797?cond=NCT04099797&draw=2&rank=1."},{"key":"ref_95","unstructured":"(2023, March 10). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04196413."},{"key":"ref_96","unstructured":"(2023, March 10). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02442297."},{"key":"ref_97","unstructured":"(2023, March 10). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03500991."},{"key":"ref_98","unstructured":"(2023, March 10). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04185038."},{"key":"ref_99","unstructured":"(2023, February 19). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03373097."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor Antigen Escape from CAR T-cell Therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e152477","DOI":"10.1172\/JCI152477","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"131","author":"Hegde","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_103","unstructured":"(2023, February 19). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02208362."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/neuonc\/nox182","article-title":"Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma","volume":"20","author":"Bielamowicz","year":"2018","journal-title":"Neuro-Oncology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-018-0759-3","article-title":"Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Cocco, C., Morandi, F., and Airoldi, I. (2021). Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes. Cells, 10.","DOI":"10.20944\/preprints202104.0016.v1"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Terry, R.L., Meyran, D., Fleuren, E.D.G., Mayoh, C., Zhu, J., Omer, N., Ziegler, D.S., Haber, M., Darcy, P.K., and Trapani, J.A. (2021). Chimeric Antigen Receptor T cell Therapy and the Immunosuppressive Tumor Microenvironment in Pediatric Sarcoma. Cancers, 13.","DOI":"10.3390\/cancers13184704"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2017.05.006","article-title":"Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies","volume":"58","author":"Park","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41577-018-0031-5","article-title":"Author Correction: Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-20-1499","article-title":"Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma","volume":"27","author":"Chastkofsky","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"vdab027","DOI":"10.1093\/noajnl\/vdab027","article-title":"Therapeutic cancer vaccines for pediatric malignancies: Advances, challenges, and emerging technologies","volume":"3","author":"Olsen","year":"2021","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00262-021-03131-y","article-title":"Pediatric glioblastoma: Mechanisms of immune evasion and potential therapeutic opportunities","volume":"71","author":"Njonkou","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Michaelides, S., Obeck, H., Kechur, D., Endres, S., and Kobold, S. (2022). Migratory Engineering of T Cells for Cancer Therapy. Vaccines, 10.","DOI":"10.3390\/vaccines10111845"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/glycob\/cwy008","article-title":"Glycan-directed CAR-T cells","volume":"28","author":"Steentoft","year":"2018","journal-title":"Glycobiology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00018-021-04089-x","article-title":"Tuning the ignition of CAR: Optimizing the affinity of scFv to improve CAR-T therapy","volume":"79","author":"Duan","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41551-021-00779-w","article-title":"Control of the activity of CAR-T cells within tumours via focused ultrasound","volume":"5","author":"Wu","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"693016","DOI":"10.3389\/fimmu.2021.693016","article-title":"CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities","volume":"12","author":"Fischer","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_121","first-page":"1","article-title":"Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and\/or siltuximab following CAR T cell therapy","volume":"434","author":"Chen","year":"2016","journal-title":"J. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/6\/2326\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:57:08Z","timestamp":1760122628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/6\/2326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":122,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["jcm12062326"],"URL":"https:\/\/doi.org\/10.3390\/jcm12062326","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]}}}